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Abstract 
Background: Measurements of anti-malarial antibodies are increasingly used as a proxy of transmission intensity. 
Most serological surveys are based on the use of cross-sectional data that, when age-stratified, approximates historical 
patterns of transmission within a population. Comparatively few studies leverage longitudinal data to explicitly relate 
individual infection events with subsequent antibody responses.
Methods: The occurrence of seroconversion and seroreversion events for two Plasmodium falciparum asexual stage 
antigens (MSP-1 and AMA-1) was examined using three annual measurements of 691 individuals from a cohort of 
individuals in a malaria-endemic area of rural east-central Tanzania. Mixed-effect logistic regression models were 
employed to determine factors associated with changes in serostatus over time.
Results: While the expected population-level relationship between seroprevalence and disease incidence was 
observed, on an individual level the relationship between individual infections and the antibody response was com-
plex. MSP-1 antibody responses were more dynamic in response to the occurrence and resolution of infection events 
than AMA-1, while the latter was more correlated with consecutive infections. The MSP-1 antibody response to an 
observed infection seemed to decay faster over time than the corresponding AMA-1 response. Surprisingly, there was 
no evidence of an age effect on the occurrence of a conversion or reversion event.
Conclusions: While the population-level results concur with previously published sero-epidemiological surveys, the 
individual-level results highlight the more complex relationship between detected infections and antibody dynamics 
than can be analysed using cross-sectional data. The longitudinal analysis of serological data may provide a powerful 
tool for teasing apart the complex relationship between infection events and the corresponding immune response, 
thereby improving the ability to rapidly assess the success or failure of malaria control programmes.
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Background
Malaria imposes a severe public health burden in tropical 
and sub-tropical regions, particularly sub-Saharan Africa 
[1]. Quantifying the impact of control strategies on expo-
sure and infection is essential to improving and scaling-
up effective strategies [2]. This is often accomplished 
by monitoring changes in incidence, prevalence and/or 
entomological estimates of malaria transmission inten-
sity [3]. One promising alternative approach is the use of 
serological measures of malaria exposure, which involves 
detecting antibodies produced by the body in response to 
an infection in a plasma or serum sample.
Anti-malarial antibody responses not only contribute 
to mediating protection from the disease, but also rep-
resent a marker of individual, and population, exposure 
history. Since antibodies persist longer in the human 
body than the parasite itself (longer, too, than the lifespan 
Open Access
Malaria Journal
*Correspondence:  ryan.simmons@duke.edu 
1 Department of Biostatistics and Bioinformatics, Duke University Medical 
Center, 2721, Durham, NC 27701, USA
Full list of author information is available at the end of the article
Page 2 of 13Simmons et al. Malar J  (2017) 16:309 
of the vector), serological markers may represent more 
robust and sensitive measurements of transmission 
intensity than entomological or parasitological markers 
[4–6]. The utility of sero-epidemiological surveillance has 
been demonstrated by numerous studies in Tanzania [7, 
8], Vanuatu [9], Equatorial Guinea [10], Brazil [11], and 
Uganda [12]. The most widely studied markers include 
antigens to the Plasmodium falciparum apical mem-
brane antigen 1 (AMA-1) and merozoite surface protein 
1 (MSP-119) recombinant proteins, both of which have 
been proposed as malaria vaccine candidates [13].
Serology has been used as a tool to measure trans-
mission intensity and monitor changes as far back as 
the 1950s. Nearly all examples of this approach employ 
cross-sectional serological surveys coupled with serocat-
alytic models to estimate the average seroconversion and 
seroreversion rates in the study population [7, 14]. Sero-
catalytic models use age as a proxy for historical time, 
treating each individual’s observed serostatus as “a ran-
dom realization of a seroconversion-seroreversion sto-
chastic law” [14]. These models often make a number of 
important assumptions, namely: that the risk of serocon-
version is directly proportional to individual exposure; 
that individual serostatus is a relatively stable state over 
time; and that seroreversion rates are stable over time, 
meaning that a fixed proportion of people will serocon-
vert as well as serorevert every year. These are assump-
tions that can only be tested in a longitudinal setting.
There have been comparatively few longitudinal assess-
ments of malaria serologic data [15–21], each with 
important limitations. Several studies were conducted in 
very low transmission settings with fewer than a dozen 
seroconversion events [15, 19], several studies followed 
participants for less than a year [19, 20], and only one 
study included older children and adults [18]. Bejon et al. 
[22] followed a cohort of individuals in Kenya for several 
years; however, the analysis was restricted to children 
under 15  years of age, and conducted separately within 
each survey year rather than longitudinally. None of these 
studies investigated individual predictors of seroconver-
sion or seroreversion events, or examined the dynamics 
of the antibody response following a detectable infection.
There is a relative lack of longitudinal data aimed at 
elucidating medium or long-term trends in antibody 
response to malaria in a large study population. Such 
insights are required to improve the use of serological 
outcomes in monitoring malaria transmission within 
large-scale control programmes. Current approaches 
have been validated to infer longitudinal trends in malaria 
transmission based on cross-sectional data but nuances 
in transmission dynamics may be missed [4, 7, 8]. 
The richer longitudinal data of the Mvomero study in 
Tanzania [23] was leveraged to examine the temporal 
dynamics of serostatus and the roles of age and malaria 
parasitaemia in shaping these dynamics. The present 
study specifically explores some of the assumptions that 
underlie cross-sectional, population-based serologi-
cal analysis, including the relationship between serosta-
tus and age, the nature of seropositive state, and rates of 
seroreversion over time.
Methods
Data sources
A longitudinal, cluster-randomized study was conducted 
in 24 randomly selected villages in Mvomero district 
in rural east-central Tanzania from 2011 to 2013. In a 
two-stage design, villages were enrolled as clusters and 
households randomly sampled from within each village; 
six study villages were assigned to each of four groups 
(control; a disease management strategy involving early 
detection and treatment by community health workers 
using rapid diagnostic technology; vector control through 
community-supported larviciding; and early detection 
and treatment plus larviciding). A cohort of 5385 people 
from 962 households (approximately 40 households per 
village) were enrolled and sampled in three consecutive 
years during the long rainy season, for a total of 16,155 
possible measurements. The first survey was conducted 
in March and April 2011, with follow-up conducted in 
the same months of 2012 and 2013. A detailed descrip-
tion of the study design can be found in Kramer et  al. 
[23].
This analysis was restricted to the sub-set of individuals 
for whom parasitological and serological outcomes, for 
either AMA-1 or MSP-1, were available at all three time 
points; namely, those with complete-case data. There 
were 681 individuals with complete-case data for AMA-
1, and 686 individuals with complete-case data for MSP-
1. There were five individuals with complete information 
for AMA-1 data who were missing at least one MSP-1 
measurement, and there were ten individuals with com-
plete MSP-1 data who were missing at least one AMA-1 
measurement. As a consequence, there were a total of 
691 individuals in the current evaluation. The age ranges, 
and other relevant characteristics, of these individuals 
are shown in Table 1.
Parasitological measures
At each annual data collection round, participants pro-
vided a finger-prick blood sample from which a dried 
blood spot was stored and a malaria smear was prepared. 
Blood spots were stored with desiccant at −20 °C prior to 
and after shipping to the London School of Hygiene and 
Tropical Medicine, with laboratory analyses conducted 
on all samples at the conclusion of the study. Thick and 
thin blood smears were stained with Giemsa solution 
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and examined with a binocular microscope with an oil 
immersion lens to quantify the parasitaemia. Parasitae-
mia was measured by counting the number of asexual 
parasites against the number of leukocytes in the blood 
film, based on a count of 8000 leukocytes per microlitre. 
The number of asexual parasites was counted against 200 
leukocytes using a hand tally counter. A slide was con-
sidered negative if no malaria parasite was observed in at 
least 200 oil-immersion fields.
Serological measures
Antibodies to malaria antigens were detected from 
serum samples of study participants using indirect 
enzyme-linked immunosorbent assays (ELISA). The 
technique is described fully in Stewart et al. [8]. Briefly, 
plasma is eluted from dried blood spots. The concen-
tration (or titre) of the antibody (measured in arbitrary 
units, AU, per microlitre) is inferred by the optical den-
sity values recorded from an ELISA reader. Raw optical 
density values are converted into an estimated titer using 
a standard curve generated by titration of a positive con-
trol sample on each assay plate. This analysis focused on 
antibodies to the P. falciparum apical membrane antigen 
1 (AMA-1; 3D7 strain) and merozoite surface protein 1 
(MSP-119; Wellcome genotype) recombinant proteins, 
which were produced as described [24, 25]. All samples 
were processed and analysed together at the conclusion 
of the study to reduce systematic variation that can arise 
between batches of reagents.
Data analysis
Two different classes of models were fitted: one using the 
continuous antibody titre as the outcome, and another 
using observed (binary) seroconversion or seroreversion 
events as the outcome. Separate models of each class 
were fitted for AMA-1 and MSP-1 (for a total of six mod-
els). Observed seroconversion events were defined as 
when an individual who was seronegative in one survey 
year became seropositive in the following year; observed 
seroreversion events were defined as when an individual 
who was seropositive in one survey year become seroneg-
ative in the following year. As such, with data from three 
consecutive years, it is only possible to identify these 
events in the final 2  years (2012 and 2013). Serostatus 
Table 1 Characteristics of Mvomero study population with complete case serology data (N = 691)
Survey 1 (2011) Survey 2 (2012) Survey 3 (2013)
Age in years (N%)
 <2 145 (21.0%) 101 (14.6%) 30 (4.3%)
 2–5 149 (21.6%)  166 (24.0%)  173 (25.0%)
 5–10 129 (18.7%) 134 (19.4%) 173 (25.0%)
 10–15 31 (4.5%) 53 (7.7%) 74 (10.7%)
 15–20 18 (2.6%) 14 (2.0%) 18 (2.6%)
 20–30 88 (12.7%) 82 (11.9%) 69 (10.0%)
 30–40 81 (11.7%) 79 (11.4%) 81 (11.7%)
 40+ 50 (7.2%) 62 (9.0%) 73 (10.6%)
Gender
 Male 272 (39.4%)
 Female 419 (60.6%)
Malaria infections
 N (%) 34 (5.0%) 47 (6.8%) 95 (14.2%)
Seropositive (AMA-1)
 N (%) 313 (45.4%) 249 (36.4%) 302 (43.9%)
Seropositive (MSP-1)
 N (%) 227 (33.0%) 192 (27.9%) 278 (40.2%)
Number of seroconversion events (AMA-1) n/a
 N (% of seronegative in previous survey) 19 (5.0%) 73 (19.7%)
Number of seroconversion events (MSP-1)
 N (% of seronegative in previous survey) 42 (9.1%) 110 (22.0%)
Number of seroreversion events (AMA-1)
 N (% of seropositive in previous survey) 81 (25.9%) 21 (8.4%)
Number of seroreversion events (MSP-1)
 N (% of seropositive in previous survey) 77 (33.9%) 26 (13.5%)
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(i.e., seropositive or seronegative) was determined by 
designating a titre threshold, above which a sample was 
deemed to be seropositive, and below which was deemed 
to be seronegative. For each antigen, this threshold was 
determined by fitting a two-component normal mixture 
model to the estimated titer distribution; the threshold 
was calculated as the mean of the ‘seronegative’ (i.e. lower 
titer) component plus three standard deviations [5].
The continuous antibody titre models were fitted as 
normal mixed-effects models [26] with natural log-trans-
formed antibody titres as the outcome and individual-
level random intercepts accounting for the correlation 
within individuals over time. For the seroconversion/
seroreversion models, the outcome was a binary indica-
tor of whether or not a seroconversion or seroreversion 
event was observed in 2012 or 2013. The model was fit-
ted as a logistic regression with random intercepts at the 
individual level. Each individual could only contribute a 
single positive outcome (i.e., could only seroconvert or 
serorevert once) to each model because there were only 
two follow-up time periods, making the comparison 
between individuals who experienced an event vs those 
who never experienced that event (e.g., an individual who 
seroconverted in 2012 did not contribute to the model 
for 2013, since they had already seroconverted).
In both classes of models, lasso variable selection was 
used to find the most parsimonious model [27]. The fol-
lowing set of possible predictors was entered: age, pres-
ence or absence of an observed malaria infection (either 
concurrent with the outcome event or in the preced-
ing year), and serostatus for the alternate antibody (i.e., 
MSP-1 as a predictor when AMA-1 is the outcome, and 
vice versa), both concurrent with the outcome event and 
in the previous year. In addition, an indicator variable for 
year (2012 vs 2013) was included to account for differ-
ences in the number of events between survey years. The 
two-way interactions for all predictors listed above were 
included in the model selection procedure. The relation-
ship between cross-sectional seroprevalence and age is 
known to follow a logistic growth curve, often modelled 
using a reversible catalytic conversion (RCC) model [7, 
28]. To account for the non-linear relationship between 
age and seropositivity, the exposure-driven relationship 
with age was modelled as a linear spline with a knot at 
age 20. Exploratory analyses determined this to be a rea-
sonable approximation, with the spline expressing a simi-
lar value for the concordance (c) statistic [29] compared 
to the corresponding RCC model for both antibodies (for 
AMA-1: spline c = 0.85, RCC c = 0.84; for MSP-1: spline 
c  =  0.72, RCC c  =  0.72). In practice, after implement-
ing the lasso approach for each outcome and for both 
antibodies, all two-way interactions were dropped from 
each of the six final models. All analyses were performed 
using SAS/STAT software, version 9.4 of the SAS System 
for Windows. Copyright © 2013 SAS Institute Inc., Cary, 
NC, USA.
Results
Descriptive statistics
The characteristics of the 691 individuals in the analysis 
sample are shown by survey year in Table  1. Most (423 
individuals, 61.3% of the sample) were below the age of 10 
years at baseline; due to aging, this shifted to 376 (54.4%) 
by the third survey. Relatively few people in this cohort 
were between the ages of 10 and 20 years, with 49 indi-
viduals in 2011 (7.1%), rising to 92 (13.3%) by 2013. One-
hundred and thirty-nine individuals (20.1%) had at least 
one malaria infection during the study; 34 individuals 
were missing a malaria status in at least one survey year. 
Of the 176 total observed malaria infections, 34 (19.3%) 
were in 2011, 47 (26.7%) were in 2012, and 95 (54.0%) 
were in 2013. There were 92 observed seroconversion 
events for AMA-1 and 152 for MSP-1 (corresponding 
to 13.5 and 22.1% of individuals, respectively). For both 
antibodies, the majority (79.3 and 72.3%, respectively) of 
seroconversion events were observed in 2013. Addition-
ally, there were 102 observed seroreversion events for 
AMA-1 and 103 for MSP-1, with the majority (79.4 and 
74.8%, respectively) being observed in 2012.
Individuals were classified by observed malaria infec-
tion ‘trajectory’-in other words, their malaria infection 
status across time in each survey year; the characteristics 
of individuals within each trajectory group are shown 
in Table  2. Thirty-four individuals with missing parasi-
taemia data were excluded. Of the 139 individuals with 
at least one detected malaria infection, 27 (19.4%) had 
multiple detected infections during the follow-up period. 
These 27 were, on average, younger than those with one 
or zero observed infections. The proportion of seroposi-
tive individuals was greater amongst participants with at 
least one observed infection (0.72 for AMA-1 and 0.68 
for MSP-1; N  =  139) than among those never infected 
(0.49 for AMA-1 and 0.45 for MSP-1; N = 518).
Table 3 shows the characteristics of the analysis popu-
lation by serostatus trajectory (i.e., individual patterns of 
serostatus over time; if 0 =  seronegative and 1 =  sero-
positive, then an individual who was never observed to be 
seropositive during the study has a trajectory of 000. An 
individual who was only seropositive in 2011 would have 
a trajectory of 100, etc.). For both antibodies, individuals 
who were seropositive at multiple time points (e.g., 110) 
were, on average, older than individuals who were never 
seropositive. Malaria infection prevalence was greater 
among individuals who were seropositive in at least one 
time point (AMA-1: 101/367 or 27.5%; MSP-1: 99/344 or 
28.8%) compared to individuals who were seronegative at 
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all time points (AMA-1: 41/314 or 13.1%; MSP-1: 45/342 
or 13.2%).
Individual log-titre values over time within each 
serostatus trajectory for both antibodies are shown in 
Fig.  1. In general, the titre levels across time reflect the 
derived serostatus trajectory; however, it is clear that 
using binary serostatus in a longitudinal framework does 
not capture the heterogeneity in the actual titre. Although 
seropositive individuals had a greater degree of variability 
in their absolute titre values, seronegative individuals also 
had a high level of variation especially if these individuals 
are interpreted as malaria-naïve or unexposed.
The distribution of log-titre by serostatus as a func-
tion of age within each survey year is shown in Fig.  2. 
The relationship between age and median titre (denoted 
on the plots by the solid line) roughly matches the loga-
rithmic growth of seroprevalence over age observed in 
cross-sectional surveys [7]. Of particular interest is the 
difference between the age trends for AMA-1 and MSP-1 
(panel A vs panel B). The slope is sharper for AMA-1 
than for MSP-1, with an apparent decline within the old-
est strata of age (though this may in part be driven by a 
smaller sample size within that strata). This is consistent 
with previously reported differences in seroprevalence 
for these antigens [7, 20].
Individual seroconversion event models
Individuals who were seronegative in one year and sero-
positive the following year (i.e., in 2011 and 2012, or in 
2012 and 2013) were defined as having seroconverted. 
Table 2 Characteristics of study population by malaria trajectory (N = 657)
0 no detectible infection, 1 detected infection (e.g., 001 denotes no detectible infection in 2011 and 2012, then an infection detected in 2013; etc.)
000 (N = 518) 001 (N = 69) 010 (N = 24) 100 (N = 19) 011 (N = 13) 101 (N = 6) 110 (N = 4) 111 (N = 4)
Age at baseline
 Mean (SD) 14.77 (16.06) 13.94 (13.95) 13.61 (13.49) 21.79 (22.73) 8.00 (8.40) 12.50 (10.39) 6.75 (3.77) 8.00 (4.24)
Gender
 Male 194 (37.5%) 32 (46.4%) 11 (45.8%) 8 (42.1%) 8 (61.5%) 2 (33.3%) 1 (25.0%) 4 (100.0%)
 Female 324 (62.5%) 37 (53.6%) 13 (54.2%) 11 (57.9%) 5 (38.5%) 4 (66.7%) 3 (75.0%) 0 (0.0%)
Seropositive at any time point (AMA-1)
 N (%) 251 (48.5%) 47 (68.1%) 15 (62.5%) 14 (73.7%) 10 (76.9%) 6 (100.0%) 4 (100.0%) 4 (100.0%)
Seropositive at any time point  (MSP-1)
 N (%) 231 (44.6%) 49 (71.0%) 20 (83.3%) 14 (73.7%) 6 (46.2%) 4 (66.7%) 2 (50.0%) 0 (0.0%)
Table 3 Characteristics of study population by serostatus trajectory
0 seronegative, 1 seropositive (e.g. 001 denotes seronegative in 2011 and 2012, then seropositive in 2013; etc.)
AMA-1 (N = 681)
000 (N = 314) 001 (N = 40) 010 (N = 12) 100 (N = 47) 011 (N = 7) 101 (N = 33) 110 (N = 9) 111 (N = 219)
Age at baseline
 Mean (SD) 5.21 (7.20) 11.52 (17.13) 14.18 (16.01) 17.48 (15.71) 16.79 (24.50) 24.35 (17.34) 30.33 (18.41) 26.59 (14.93)
Gender
 Male 147 (46.8%) 21 (52.5%) 2 (16.7%) 17 (36.2%) 3 (42.9%) 14 (42.4%) 4 (44.4%) 59 (26.9%)
 Female 167 (53.2%) 19 (47.5%) 10 (83.3%) 30 (63.8%) 4 (57.1%) 19 (57.6%) 5 (55.6%) 160 (73.1%)
Infected at any time point
 N (%) 41 (13.1%) 10 (25.0%) 3 (25.0%) 6 (12.8%) 5 (71.4%) 8 (24.2%) 0 (0.0%) 69 (31.5%)
MSP-1 (N = 686)
000 (N = 342) 001 (N = 75) 010 (N = 17) 100 (N = 43) 011 (N = 25) 101 (N = 34) 110 (N = 9) 111 (N = 141)
Age at baseline
 Mean (SD) 10.18 (12.70) 10.49 (15.41) 6.81 (9.89) 13.81 (14.60) 7.64 (9.89) 20.40 (17.16) 34.94 (19.73) 28.50 (15.14)
Gender
 Male 152 (44.4%) 36 (48.0%) 8 (47.1%) 17 (39.5%) 11 (44.0%) 11 (32.4%) 3 (33.3%) 34 (24.1%)
 Female 190 (55.6%) 39 (52.0%) 9 (52.9%) 26 (60.5%) 14 (56.0%) 23 (67.6%) 6 (66.7%) 107 (75.9%)
Infected at any time point
 N (%) 45 (13.2%) 28 (37.3%) 8 (47.1%) 5 (11.6%) 8 (32.0%) 5 (14.7%) 2 (22.2%) 43 (30.5%)
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Those who seroconverted were compared to those who 
remained seronegative in a mixed-effects logistic regres-
sion. Table 4 shows the odds ratios for seroconverting for 
AMA-1 and MSP-1. Individuals had 3.6 [95% confidence 
interval (CI) 2.1–6.2] times greater odds of seroconvert-
ing for AMA-1 in 2013 than in 2012, and 2.8 (95% CI 
Fig. 1 Individual log titre trajectories across survey years. For AMA-1 (a) and MSP-1 (b) by serostatus classification (0 seronegative, 1 seropositive;  
e.g. 001 denotes seronegative in 2011 and 2012, then seropositive in 2013, etc.)
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Fig. 2 Age-stratified seroprevalence curves in each survey years. For AMA-1 (a) and MSP-1 (b). The points denote an individual’s log-titre value for 
the respective antibody in the given survey year, colored red for titres classified as seropositive and blue for titres classified as seronegative. The solid 
lines connect the median log-titre within each age group
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1.9–4.3) times greater odds for MSP-1. Age did not sig-
nificantly impact individual odds of seroconverting for 
AMA-1, but did for MSP-1: individuals 20  years of age 
and younger were slightly less likely to seroconvert (OR 
0.93, 95% CI 0.89–0.97) while individuals older than 20 
were slightly more likely to seroconvert (OR 1.08, 95% 
CI 1.02–1.16). Individuals who seroconverted to the 
alternate antigen were significantly more likely to sero-
convert to the outcome antigen, compared to individu-
als who remained seronegative across both years to the 
alternate antigen: MSP-1 seroconversion (in a given year) 
was associated with 2.79-fold (95% CI 1.64–4.76) higher 
odds of AMA-1 seroconversion in that same year, while 
AMA-1 seroconversion was associated with 3.93-fold 
(95% CI 2.26–6.81) higher odds of MSP-1 seroconver-
sion. Seroreversion to the alternate antigen, on the other 
hand, was associated with significantly reduced odds of 
seroconversion to the outcome antigen (compared to 
individuals who remained seronegative across both years 
to the alternate antigen): the odds of seroconverting for 
AMA-1 was multiplied by 0.25 (95% CI 0.13–0.50) when 
a seroreversion was observed for MSP-1 compared to 
those who did not experience a seroreversion. The odds 
ratio of seroconverting for MSP-1 when a seroreversion 
for AMA-1 was observed in the same year was 0.50 (95% 
CI 0.28–0.90). Being seropositive in both years for MSP-1 
did not impact the odds of AMA-1 seroconversion (OR 
0.70, 95% CI 0.36–1.34) compared to being seronega-
tive in both years for MSP-1. However, for those who 
were being positive for AMA-1 in both years, the odds 
of MSP-1 seroconversion was multiplied by 1.97 (95% CI 
1.10–3.51), compared to being negative in both years.
In the AMA-1 model, neither concurrent (OR 1.34, 
95% CI 0.70–2.54) or preceding year (OR 2.07, 95% CI 
0.94–4.56) malaria infection status (at the time of sam-
pling) was a significant predictor of seroconversion, com-
pared to individuals without an infection in either year. 
However, individuals who had a malaria infection in both 
years had 2.77 (95% CI 1.11–6.89) times higher odds of 
seroconverting compared to individuals without an infec-
tion in either year. By contrast, in the MSP-1 model, 
those who did not have an observed malaria infection 
in the preceding year but did have one in the concurrent 
year were significantly more likely to MSP-1 seroconvert 
than individuals with no observed malaria infections in 
either year (OR 2.70, 95% CI 1.65–4.42). Individuals who 
did not have a malaria infection in the concurrent year 
but did in the preceding year were significantly less likely 
to MSP-1 seroconvert (OR 0.37, 95% CI 0.15–0.95). Hav-
ing a malaria infection in both years was not associated 
with any difference in the odds of MSP-1 seroconversion 
(OR 1.00; 95% CI 0.38–2.68), compared to individuals 
with no observed infections.
Individual seroreversion event models
Using a similar principle as for seroconversion, a seror-
eversion event was defined as when an individual who 
was seropositive in a given year (2011 or 2012) was 
seronegative in the following year (2012 or 2013). Those 
who seroreverted were compared to those who remained 
seropositive in a mixed-effects logistic regression. Table 4 
shows the odds ratios for the analogous seroreversion 
models for AMA-1 and MSP-1. For both antigens, indi-
viduals were less likely to serorevert in 2013 than in 2012 
(for AMA-1: OR =  0.31, 95% CI  0.19–0.53; for MSP-1: 
OR  0.43, 95% CI  0.26–0.79). For AMA-1, individuals 
20 years or younger in age were more likely to serorevert 
(OR 1.06; 95% CI 1.02–1.10). Older individuals were no 
more or less likely to serorevert for AMA-1, and neither 
age effect was significant in the MSP-1 model. Individu-
als who seroreverted to the alternate antigen in the same 
time frame were significantly more likely to serorevert 
to the outcome antigen, compared to individuals who 
remained seropositive in both years: seroreversions for 
MSP-1 were associated with increased odds of seror-
everting for AMA-1 (OR 3.21; 95% CI 1.72–6.02) while 
seroreversions for AMA-1 were associated with 2.58-
fold (95% CI 1.41–4.74) greater odds of seroreverting for 
MSP-1. Meanwhile, seroconverting to the alternate anti-
gen was associated with reduced odds of seroreverting 
Table 4 Odds ratios (and 95% CIs) from  mixed-effects 
logistic regression models for  each outcome (serocon-
versions and  seroreversions) on  each antibody (AMA-1 
and MSP-1)
Italicized cells indicate statistical significance
Outcome
Parameter Seroconversion Seroreversion
OR (95% CI) OR (95% CI)
AMA-1
 Year (2013 vs 2012) 3.56 (2.06, 6.15) 0.31 (0.19, 0.53)
 Age (≤20) 0.99 (0.95, 1.04) 1.06 (1.02, 1.10)
 Age (>20) 1.04 (0.97, 1.11) 0.95 (0.90, 1.01)
 Malaria in current year 1.34 (0.70, 2.54) 0.73 (0.28, 1.91)
 Malaria in previous year 2.07 (0.94, 4.56) 0.51 (0.15, 1.71)
 MSP-1 seropositive in current year 2.79 (1.64, 4.76) 0.31 (0.16, 0.58)
 MSP-1 seropositive in previous year 0.25 (0.13, 0.50) 2.01 (1.15, 3.51)
MSP-1
 Year (2013 vs 2012) 2.84 (1.89, 4.25) 0.43 (0.26, 0.79)
 Age (≤20) 0.93 (0.89, 0.97) 1.00 (0.96, 1.05)
 Age (>20) 1.08 (1.02, 1.16) 1.01 (0.95, 1.08)
 Malaria in current year 2.70 (1.65, 4.42) 0.98 (0.45, 2.09)
 Malaria in previous year 0.37 (0.15, 0.95) 1.95 (0.89, 4.25)
 AMA-1 seropositive in current year 3.93 (2.26, 6.81) 0.39 (0.21, 0.71)
 AMA-1 seropositive in previous year 0.50 (0.28, 0.90) 2.58 (1.39, 4.81)
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to the outcome antigen, compared to individuals who 
remained seropositive in both years: individuals who 
seroconverted for MSP-1 were 0.50 (95% CI 0.29–0.87) 
as likely to serorevert for AMA-1, while individuals who 
seroconverted for AMA-1 were 0.40 (95% CI 0.21–0.72) 
as likely to serorevert for MSP-1. In both cases, the 
odds of seroreversion to the outcome antigen was not 
impacted by remaining seronegative to the alternate anti-
gen in both years (for AMA-1, OR 1.60, 95% CI 0.89–
2.86; for MSP-1, OR 1.00, 95% CI 0.53–1.90).
Having a malaria infection in the current, previous or 
both years was not significantly associated with AMA-1 
seroreversion compared to individuals without any 
observed infections. For MSP-1, having an observed 
malaria infection in the previous year but not the cur-
rent year was associated with higher odds of serorevert-
ing (OR 1.95; 95% CI 0.89–4.25) compared to individuals 
without an infection in either year, but the effect was not 
statistically significant. Neither concurrent malaria infec-
tions (OR 0.98; 95% CI 0.45–2.09) nor having a malaria 
infection in both years (OR 1.90; 95% CI 0.69–5.23) were 
significantly related to the odds of MSP-1 serorever-
sion, again compared with individuals with no observed 
infections.
Continuous titre models
The continuous titre models were fitted as mixed-effects 
models with the natural log-transformed titre values for 
each antibody as the outcome. Table 5 shows the param-
eter estimates for the continuous antibody titre models 
for AMA-1 and MSP-1. Average log-titres were higher in 
2013 than 2012 for both antibodies (AMA-1: 0.11, 95% 
CI 0.04–0.18; MSP-1: 0.45, 95% CI 0.35–0.56). Antibody 
titre in a given year is most strongly correlated to the titre 
in the previous year (AMA-1: 0.75, 95% CI 0.72–0.79); 
MSP-1: 0.68, 95% CI 0.64–0.72). Titre was significantly 
higher in participants with a concurrent malaria infec-
tion (AMA-1: 0.27, 95% CI 0.16–0.38; MSP-1: 0.29, 95% 
CI 0.12–0.47). Antibody titres in the concurrent year 
were correlated: a one unit increase in MSP-1 titre was 
associated with a 0.21 (95% CI 0.18–0.25) increase in 
AMA-1 titre, and a one-unit increase in AMA-1 titre was 
associated with a 0.53 (95% CI 0.45–0.61) unit increase in 
MSP-1 titre. There was an inverse relationship between 
outcome antibody titre and titre for the alternate anti-
body in the previous year. Log AMA-1 titre decreased 
by 0.11 (95% CI 0.07–0.14) for each one-log increase in 
MSP-1 titre in the previous year. A similar relationship is 
observed for MSP-1 titre, which decreased by 0.34 (95% 
CI 0.25–0.42) for each one log increase in AMA-1 titre 
in the previous year. The major difference between the 
two antibodies is the direction of the effect for observed 
malaria infections in the preceding year. For AMA-1, an 
observed malaria infection in the preceding year, but not 
the concurrent year, was significantly associated with 
higher log-titre (0.15; 95% CI 0.01–0.29). The opposite 
effect was observed for MSP-1 titre; malaria infection in 
the preceding year was associated with lower log-titre in 
the concurrent year (−0.34; 95% CI −0.42 to 0.25).
Discussion
This study describes antibody responses to malaria anti-
gens in samples collected over a 3-year period from a 
cohort in a malaria-endemic population. The profiles 
of these responses over time were more dynamic than 
anticipated: seroreversion events were just as common 
as seroconversion events (in fact, for AMA-1, they were 
more common). Further, the number of events changed 
dramatically between subsequent surveys, with a 300% 
increase in the total number of seroconversion events 
between 2011 and 12 and 2012 and 13 and a correspond-
ing 70% reduction in the total number of seroreversion 
events over the same time period, which parallels changes 
in infection prevalence estimates between the surveys. In 
contrast, studies using cross-sectional data often assume 
static rates over time, especially for seroreversion [4, 7, 
14, 15]. Although there are extensions of these methods 
designed to detect changes in the seroconversion rate at 
specific points in time, for model-fitting purposes these 
often treat the seroreversion rate as fixed [8, 30].
Despite the well-studied relationship between age and 
population-level seroprevalence that forms the basis of 
most cross-sectional models, such as the reversible cat-
alytic conversion and superinfection models [7, 10, 30], 
the present analyses of individual-level changes across 
years found age to have very little role in predicting indi-
vidual titre levels or the incidence of individual serocon-
version or seroreversion events. This concords with the 
Table 5 Parameter estimates (and 95% CIs) from  normal 
mixed-effects models for each antibody (AMA-1 and MSP-
1)
Italicized cells indicate statistical significance
Parameter AMA-1 MSP-1
Estimate (95% CI) Estimate (95% CI)
Year (2013 vs 2012) 0.11 (0.04, 0.18) 0.45 (0.35, 0.56)
Malaria in current year 0.27 (0.16, 0.38) 0.29 (0.12, 0.47)
Malaria in previous year 0.15 (0.01, 0.29) −0.35 (−0.57, −0.13)
AMA-1 log-titre in current 
year
n/a 0.53 (0.45, 0.61)
AMA-1 log-titre in previous 
year
0.75 (0.72, 0.79) −0.34 (−0.42, −0.25)
MSP-1 log-titre in current year 0.21 (0.18, 0.25) n/a
MSP-1 log-titre in previous 
year
−0.11 (−0.14, 
−0.07)
0.68 (0.64, 0.72)
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findings of Yman et al. [31] and Wipasa et  al. [32], who 
both observed a lack of a distinct age effect on individual 
antibody titres. This implies that change in serostatus 
may be solely governed by age-independent exposures, 
and it is the accumulation of these exposures over time 
that results in age-dependent seroprevalence patterns, 
rather than the mechanisms of change themselves being 
a function of age. While there were few age-related 
effects on change in serostatus in this study, on average 
the individuals with multiple observed detectable infec-
tions were younger than individuals with one or fewer 
infections. It is possible that the greater number of infec-
tions in the youngest individuals resulted in higher anti-
body responses, whereas adults were either infected less 
frequently or had sub-microscopic infections that served 
to maintain antibody response levels.
As expected, on a population level, the occurrence of 
seroconversion and seroreversion events tracked with 
changes in the number of observed infection events, 
with higher incidence of malaria associated with a higher 
number of seroconversions for both antibodies [4, 10, 
12, 20, 33]. The increase in seroconversion events and 
decrease in seroreversion events between 2011 and 2012 
and 2012 and 2013 corresponded with a twofold increase 
in the number of observed malaria infections. However, 
the individual-level models demonstrated more complex 
dynamics at work, with different patterns and magnitudes 
of responsiveness for AMA-1 and MSP-1 to the intro-
duction, resolution and sustenance of detectible infec-
tions. Seroconversion for MSP-1 was related to changes 
in infection status (with subsequent infections associated 
with greater odds and resolved infections associated with 
lower odds). However, seroreversion was not sensitive to 
such changes. Meanwhile, changes in AMA-1 serosta-
tus were not especially sensitive to changes in infection 
status, but consecutive (or repeated) infections in subse-
quent survey years were associated with significantly ele-
vated odds of seroconversion. Overall, MSP-1 appeared 
to be more sensitive to ‘short-term’ (i.e., 1 year) changes 
in infection status while AMA-1 was more sensitive to 
‘long-term’ (i.e., 2 year) changes. However, interpretation 
is limited by the lack of complete infection histories for 
the individuals in this cohort.
The present results differ from some of the common 
assumptions made by cross-sectional analyses; further 
analysis of longitudinal serologic data may reveal more 
complexities that cross-sectional methods are ill suited 
to fully capture. For example, between 2011 and 2012, 
the number of observed seroreversion events for both 
antibodies were markedly higher than the number of 
seroconversion events, despite a slight increase in the 
observed number of malaria infections. This suggests 
the possibility that there was a change in transmission 
intensity not directly observable through looking at 
prevalence alone. The apparent relationship between 
seroreversion and exposure implies that changes in seror-
eversion rates (and not just a reduction in seroconversion 
rates as in many cross-sectional studies) may be a useful 
monitoring tool for understanding changes in exposure, 
particularly in the context of a highly effective prevention 
intervention. Further, a cross-sectional approach using 
standard serocatalytic models is ill suited to estimating 
seroreversion rates [15, 34], and would have underesti-
mated the change in seroconversion and seroreversion 
rates observed between survey years.
The results from the continuous titre models support 
the inferences from the seroevent-based models. The 
increased odds of a seroconversion event, and decreased 
odds of a seroreversion event, between the 2012 and 2013 
survey years coincides with both an increase in the aver-
age log-titre levels for both antibodies from 2012 to 2013 
and a concomitant increase in the number of observed 
infections. It was also observed that if an individual’s 
log-titre increases for one antibody, it will, on average, 
increase for the other during the same time frame. This 
reflects the same phenomenon whereby if an individual 
seroconverts for one antibody they are more likely to 
seroconvert for the other. Similarly, the negative coeffi-
cient for alternate antibody in the previous year suggests 
that if an individual seroreverts for one antibody they are 
less likely to seroconvert for the other. For both AMA-1 
and MSP-1, changes in serostatus were correlated, but 
maintaining serostatus for one antigen did not affect the 
odds of seroconversion or seroreversion for the other.
Concurrent malaria infections were associated with 
increased average log-titre levels for both antibodies. 
However, previous malaria infections were associated 
with significantly increased log-titre for AMA-1, but 
significantly decreased log-titre for MSP-1. Consecu-
tive infection statuses were associated with significantly 
increased log-titre for AMA-1, but did not impact aver-
age log-titre levels for MSP-1. This would seem to imply 
that, while antibody titre is elevated for both during an 
infection, the response is preserved over a longer time 
frame for AMA-1 than for MSP-1, which may begin to 
clear more rapidly following the resolution of the infec-
tion. This would account for the differential effects of 
previous year infection status and consecutive infec-
tion statuses on outcomes between the AMA-1 models 
and the MSP-1 models. Serological and parasite based 
analysis may be operating on different temporal scales, 
something that is reflected in both the time required to 
mount a response and the persistence of antibodies fol-
lowing infection. More work remains to be done to refine 
the statistical methods necessary to most efficiently lev-
erage continuous serologic data. However, this study 
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demonstrates that the serostatus-based and titre-based 
models can produce complementary results in a longitu-
dinal framework.
The stimulation of these antibodies as a response to 
known infection events is not well understood, and is 
further complicated by boosting due to repeated infec-
tions [35]. While some studies have demonstrated rapid 
acquisition and clearance patterns in response to clinical 
malaria infections [36–38], others have found responses 
to be more persistent over time [5, 7, 32]. The presence 
or absence of symptoms or parasite densities may influ-
ence the response profile of the antibodies, which may 
be related to acquired immunity as a function of lifetime 
exposure patterns [16, 20]. Although some studies have 
compared the results of separate models of antibody 
responses, the examination of the relationship between 
the response of different antibodies within the same 
model, as done in the present study, has been an under-
explored area of research [17, 21].
One strength of the present study is that the continu-
ous titre models have the outcome antibody titre in the 
previous year as a predictor of that antibody titre in the 
current year. The magnitude of that coefficient gives an 
estimate of the degree to which an antibody response is 
maintained on a year-to-year basis, controlling for both 
infection status at point of sampling and titre for the 
alternate antibody. This would seem to further support 
the notion that the MSP-1 response decays at a faster 
rate than AMA-1, since the degree to which elevated 
titre in the previous year is associated with current titre 
is reduced. Although this would contrast with the find-
ings of Akpogheneta et al. [17], who did not identify any 
differences between the short-term response dynamics 
of AMA-1 and MSP-1, this interpretation supports the 
findings of White et al. [21], who calculated shorter half-
lives for long-lasting antibody-secreting cells to MSP-1 
compared to AMA-1, and Wipasa et al. [32].
There are several important limitations to this study. 
The sub-set of individuals included in the analysis (i.e., 
individuals with serological data at all three surveys) rep-
resents a biased sample from the overall Mvomero study 
population: e.g., there were more children under five and 
adult women used in this analysis compared to the over-
all sample. However, that these characteristics were not 
associated with any of our outcomes mitigates concerns 
about the influence of selection bias on the interpreta-
tion of the results [39]. Further, the number of seroposi-
tive (for both antibodies) and infection events per survey 
in our subset were comparable with those in the overall 
sample.
The classification of individuals as seropositive and 
seronegative makes a number of assumptions regarding 
the distribution of antibody titre in the population and 
how it relates to discrete biological states [40]. Although 
some of the ‘observed’ events are likely to be spurious (i.e., 
incurred by the assumption of a fixed titre cut-off sepa-
rating distinct positive and negative sub-populations), 
there is no a priori reason to assume that this impacts 
seroreversion estimates any more or less so than it does 
seroconversion estimates (for example, misclassification 
may be expected to result in a global over- or underes-
timation of the rate of change of serostatus within the 
population, but not to preferentially misclassify individu-
als as having seroreverted compared to seroconverted or 
vice versa). Further, this is a limitation shared by other 
analytic frameworks for estimating population serody-
namics and is not specific to this study, while the general 
agreement between the sero-event-based and continuous 
titre models assuages concerns over the validity of the 
dichotomization.
Finally, the present study relies on serological and para-
sitological measurements taken a year apart during the 
March–April rainy season. It is possible that this does 
not give a granular enough picture of individual infection 
or titre trajectories over time to make positive determi-
nations about the way these trajectories are shaped by 
infection events. Undoubtedly, many infection events 
went unobserved between the sampling time-points; in 
addition, submicroscopic infections, which may poten-
tially make up a large proportion of all malaria infections 
[41], would not have been detected in this study. How-
ever, this is no different from cross-sectional surveys that 
use age-stratified seroprevalence curves as proxies for 
cumulative exposure over time [7]. Further, more work 
needs to be done to understand the relevance of submi-
croscopic infections on malaria transmission, surveil-
lance, and control. Despite this, the concordance of this 
study’s results with those reported in other studies gives 
confidence that these limitations do not invalidate the 
conclusions drawn.
Conclusions
The potential of serologic data in malaria surveil-
lance in a variety of transmission settings has long been 
acknowledged [5]. Several authors have used retrospec-
tive analyses of repeated cross-sectional surveys to track 
population-level changes in malaria transmission using 
serologic data [42–44]. Such cross-sectional analyses of 
malaria serology data have been proposed as a tool for 
surveillance, with shifts in the age-stratified seropreva-
lence curves used to identify the success or failure of 
malaria control programmes [4, 8, 43]. This approach has 
been shown to perform well in estimating medium and 
long-term trends [7, 14]. However, these cross-sectional 
methods use age as a substitute for time, and any judge-
ments of a control programme’s success can only be 
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made after cohorts of programme-exposed individuals 
have made their way through the population age struc-
ture. Thus, it may take years for the effect of a programme 
on seroprevalence to become detectible if relying solely 
on long-lived antigens of exposure such as AMA-1 and 
MSP-1. These methods are useful for providing an over-
view of average transmission levels in the population or 
for evaluating consistent and sustained changes in expo-
sure over several years; however, they are limited in their 
ability to detect short term changes. They are further 
limited by an inability to adjust for individual-level differ-
ences in patterns of exposure over time.
Longitudinal methods, on the other hand, can model 
time directly; the indicator variable for survey year in 
the models used in these analyses may act as a direct 
measurement of year-to-year fluctuations in exposure 
across the study population. Longitudinal surveillance of 
events is likely to be more sensitive than cross-sectional 
methods, particularly to short-term changes in malaria 
exposure. The present study demonstrates that longitu-
dinal serostatus and titre changes track with other met-
rics of transmission (e.g., prevalence), while also offering 
additional insight not possible through prevalence or 
cross-sectional methods alone (e.g., the occurrence of 
seroreversion events between survey years). The simul-
taneous modelling of multiple antigens with different 
response dynamics offers a novel method for potentially 
shedding light on the timing of changes in exposure. Fur-
ther, this approach highlights the potential of the use of 
the continuous variable of antibody titres in repeated 
sampling for determining the efficacy of a programme.
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